The features of a humoral response in patients with COVID-19
- Authors: Generalova L.V1, Burgasova O.A1,2, Gushchin V.A3,2, Kolobukhina L.V2, Bakalin V.V1, Tetova V.B1, Odnoralov M.A1, Generalov E.A3
-
Affiliations:
- Peoples Friendship University of Russia
- N.F. Gamaleya National Research Center for Epidemiology and Microbiology
- M.V. Lomonosov Moscow State University
- Issue: Vol 32, No 12 (2021)
- Pages: 5-11
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114518
- DOI: https://doi.org/10.29296/25877305-2021-12-01
- ID: 114518
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
L. V Generalova
Peoples Friendship University of Russia
O. A Burgasova
Peoples Friendship University of Russia; N.F. Gamaleya National Research Center for Epidemiology and Microbiology
V. A Gushchin
M.V. Lomonosov Moscow State University; N.F. Gamaleya National Research Center for Epidemiology and Microbiology
L. V Kolobukhina
N.F. Gamaleya National Research Center for Epidemiology and Microbiology
V. V Bakalin
Peoples Friendship University of Russia
V. B Tetova
Peoples Friendship University of Russia
M. A Odnoralov
Peoples Friendship University of Russia
E. A Generalov
M.V. Lomonosov Moscow State University
References
- Russell B., Moss C., George G. et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020; 14: 1022. DOI: 10.3332/ ecancer.2020.1022
- Козлов В.А., Савченко А.А., Кудрявцев И.В. и др. Клиническая иммунология. Красноярск: Поликор, 2020; 386 с. doi: 10.17513/np.438
- Haslbauer J., Matter M., Stalder A. et al. Histomorphological patterns of regional lymph nodes in COVID-19 lungs. Pathologe. 2021; 42 (1): 89-97. doi: 10.1007/s00292-021-00945-6
- Moon C. Fighting COVID-19 exhausts T. cells. Nat Rev Immunol. 2020; 20: 277. doi: 10.1038/s41577-020-0304-7
- Shi Y., Wang Y., Shao C. et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27: 1451-4. doi: 10.1038/s41418-020-0530-3
- Guo L., Ren L., Yang S. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 778-85. doi: 10.1093/cid/ciaa310
- Гудима Г.О., Хаитов Р.М., Кудлай Д.А. и др. Молекулярноиммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции. Иммунология. 2021; 42 (3): 198-210 doi: 10.33029/0206-4952-2021-42-3-198-210
- Zhao J., Yuan Q., Wang H. et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71 (16): 2021-34. doi: 10.1093/cid/ciaa344
- Wu L.P., Wang N.C., Chang Y.H. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007; 13: 1562-4. doi: 10.3201/eid1310.070576
- Qu J., Wu C., Li X. et al. Profile of immunoglobulin G. and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255-8. doi: 10.1093/cid/ciaa489
- Wolfel R., Corman V., Guggemos W. et al. Virological assessment of hospitalized patients with C0VID-2019. Nature. 2020; 581 (7809): 465-9. doi: 10.1038/s41586-020-2196-x
- Dan J., Mateus J., Kato Y.et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2020.11.15.383323. doi: 10.1101/2020.11.15.383323
- Qu J., Wu C., Li X. et al. Profile of Immunoglobulin G. and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255-8. doi: 10.1093/cid/ciaa489
- Wolfel R., Corman M., Guggemos W. et al. Virological assessment of hospitalized patients with C0VID-2019. Nature. 2020; 581: 465-9. DOI: 10.1038/ s41586-020-2196-x
- Denning D., Kilcoyne A., Ucer C. Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. Br Dent J. 2020; 229: 521-4. doi: 10.1038/s41415-020-2228-9
- Addetia A., Crawford K.H.D., Dingens A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin Microbiol. 2020; 58 (11): e02107-20. doi: 10.1128/JCM.02107-20
- Pray I., Gibbons-Burgener S., Rosenberg A. et al. COVID-19 outbreak at an overnight summer school retreat - Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (43): 1600-4. doi: 10.15585/mmwr.mm6943a4
- Jeffery-Smith A., lyanger N., Williams S. et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021; 26 (5): 2100092. doi: 10.2807/1560-7917
- Li K., Huang B., Wu M. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6004. doi: 10.1038/s41467-020-19943-y
- Haddad N., Nguyen D., Kuruvilla M. et al. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection. bioRxiv. 2020.12.04.410589. doi: 10.1101/2020.12.04.410589
- Jiang S., Hillyar C., Du L. et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41 (5): 355-9. doi: 10.1016/j.it.2020.03.007
- Benner S., Patel E., Laeyendecker 0. et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J. Infect Dis. 2020; 222 (12): 1974-84. doi: 10.1093/infdis/jiaa581
- Valdez-Cruz N., Garcia-Hernandez E., Espitia C. et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact. 2021; 20 (1): 88. DOI: 10.1186/ s12934-021-01576-5
- Chia W.N., Zhu F., Ong S.W.X. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240-e249. doi: 10.1016/S2666-5247(21)00025-2
- Kening L., Bin H., Min W. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6044. doi: 10.1038/s41467-020-19943-y
- Jiang H., Li Y., Zhang H. et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020; 11 (1): 3581. doi: 10.1038/s41467-020-17488-8
- Whitcombe A., McGregor R., Craigie A. et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin Transl Immunol. 2021; 10 (3): e1261. doi: 10.1002/cti2.1261
- Guo L., Ren L., Yang S. et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 7778-85. doi: 10.1093/cid/ciaa310
- Kohmer N., Westhaus S., Ruhl C. et al. Clinical performance of different SARS-CoV-2 IgG antibody tests. J. Med Virol. 2020; 92 (10): 2243-7. DOI: 10.1002/ jmv.26145
- Li G., Chen X., Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl J. Med. 2003; 349 (5): 508-9. DOI: 10.1056/ NEJM200307313490520
- Qu J., Wu C., Li X. et al. Profile of IgG and IgM antibodies against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 27: ciaa489. doi: 10.1093/cid/ciaa489
- Deeks J., Dinnes J., Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6 (6): CD013652. doi: 10.1002/14651858.CD013652
- Long Q., Tang X., Shi Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26: 1200-4 DOI: 10.1038/ s41591-020-0965-6
- Lei Q., Li Y., Hou H. et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021; 76 (2): 551-61. DOI: 10.1111/ all.14622
- Chia W., Zhu F., Ong S. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240-e249. doi: 10.1016/S2666-5247(21)00025-2
- Wang C., Li W., Drabek D. et al.A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11 (1): 2251. doi: 10.1038/s41467-020-16256-y
Supplementary files
![](/img/style/loading.gif)